Compare APT & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | BEAT |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 49.3M |
| IPO Year | 1995 | 2021 |
| Metric | APT | BEAT |
|---|---|---|
| Price | $5.25 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 47.5K | ★ 694.1K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $59,096,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.06 | $0.54 |
| 52 Week High | $6.20 | $4.00 |
| Indicator | APT | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 30.41 |
| Support Level | $4.96 | $1.29 |
| Resistance Level | $5.64 | $1.47 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 40.58 | 0.83 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.